Business Wire

Warburg Pincus Establishes European Defence Investment Platform

10.4.2026 09:00:00 CEST | Business Wire | Press release

Share

Warburg Pincus launches European Defence Investment Initiative with MEAG on behalf of Munich Re Group as an Early Backer of the StrategyCollaboration Focused on Private Equity Investments in European Defence, Security and Strategic Resilience Businesses

Warburg Pincus, the pioneer of private equity global growth investing, today announced the commencement of a dedicated European defence investment platform, reflecting the firm’s view that the sector is benefiting from sustained structural tailwinds and long-term policy support across the region. MEAG, as asset manager of Munich Re Group, will support the strategy as an early backer in the investment platform.

The proposed investment platform will complement existing capabilities while maintaining a dedicated European defence focus. As European governments and institutions accelerate investment in defence capabilities, resilience and strategic sovereignty, the proposed platform seeks to position Warburg Pincus to deploy capital into defence and adjacent strategic industries across Europe.

“Europe is undergoing a fundamental reassessment of its defence, resilience and security needs, leading to significant need for scaling of the European Defence sector,” said Tobias Weidner, Managing Director and head of the European Industrials team at Warburg Pincus. “We believe this creates a compelling long-term opportunity to support the growth of high-quality businesses operating in critical, strategic sectors, drawing on our experience investing in Aerospace and Defence and broader industrials.”

“Defence and security are strategically important sectors, given their role in supporting European resilience. Warburg Pincus is a natural partner based on our long-standing relationship and their deep sector expertise in Aerospace and Defence with a multi-decade track record building market-leading companies. We look forward to working together to back high-quality European businesses in this space,” said Nicholas Gartside, Member of the Board of Munich Re and Chief Investment Officer of Munich Reinsurance Company.

Warburg Pincus has a long track record of partnering with management teams and founders across Europe and globally. The firm brings significant experience across core Aerospace and Defence and adjacent industrial sectors globally, supported by more than 20 years of industrials investing and over 40 years of investing in Europe through multiple economic cycles. Current and former Aerospace and Defence platforms include Consolidated Precision Products (CPP), Triumph Group, INRCORE, Wencor Group, Extant Aerospace and TransDigm in the U.S., Inmarsat and Accelya in Europe and Quest Global in India.

In recent years, Warburg Pincus has also further strengthened its senior advisory capabilities in the defence and national security space, assembling a group of highly experienced European and transatlantic leaders. This includes:

  • Admiral Joachim Georg Rühle (Retired 4 Star Admiral), former Chief of Staff at NATO’s Supreme Headquarters Allied Powers Europe (SHAPE) and former Vice Chief of Defence of the German Armed Forces;
  • Susanne Wiegand, a senior executive with more than 20 years of leadership experience across the defence, mechanical engineering and marine industries, including as Chair and CEO of RENK Group AG and former CEO of Rheinmetall’s Electronic Solutions division;
  • Lieutenant General Jürgen-Joachim von Sandrart (Retired 3 Star General), with four decades of service in the German Army and former commander of NATO’s Multinational Corps Northeast and a senior advisor on security and defence policy in Germany; and
  • Rolf Wirtz, a senior defence executive and former officer in the German armed forces, with decades of leadership across military aircraft and UAV, defence electronics, and naval systems, including as CEO of Atlas Elektronik and as CEO of TKMS.

This deep bench of advisors is expected to work closely alongside the firm’s experienced Aerospace and Defence investment professionals based across Europe and the U.S., combining strategic, operational and policy expertise with Warburg Pincus’ global sourcing capabilities and value-creation platform.

About Warburg Pincus

Warburg Pincus LLC is the pioneer of global growth investing. A private partnership since 1966, the firm has the flexibility and experience to focus on helping investors and management teams achieve enduring success across market cycles. Today, the firm has more than $100 billion in assets under management, and more than 215 companies in its active portfolio, diversified across stages, sectors, and geographies. Warburg Pincus has invested in more than 1,100 companies across its private equity, real estate, and capital solutions strategies.

The firm is headquartered in New York with more than 15 offices globally. For more information, please visit www.warburgpincus.com or follow us on LinkedIn and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260410960904/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye